Introduction: Beta-lactams are at the cornerstone of therapy in critical care settings, but their
clinical efficacy is challenged by the rise in bacterial resistance. Infections with multi-drug …

Objectives: This study evaluated the in vitro pharmacodynamics of combinations of
ceftazidime and the non-β-lactam β-lactamase inhibitor, avibactam, against ceftazidime …

Abstract Background and Objective Prolonged infusion of ceftolozane/tazobactam (C/T) is a
strategy used to increase achievement of pharmacokinetic/pharmacodynamic targets for the …

Consolidated data from pharmacokinetic and pharmacodynamic studies support the
administration of β-lactam antibiotics in prolonged infusion (ie, extended or continuous) to …

P. aeruginosa is still one of the most threatening pathogens responsible for serious hospital-
acquired infections. It is intrinsically resistant to many antimicrobial agents and additional …

Abstract Ceftolozane/tazobactam (C/T) has emerged as a potential agent for the treatment of
extensively drug-resistant (XDR) Pseudomonas aeruginosa infections. As it is a time …

The aim of the study was to determine the efficacy of dual β-lactam combination treatments
derived from eight approved drugs against Galleria mellonella larvae infected with MDR …

Background The optimal antibiotic regimen for Pseudomonas aeruginosa bacteremia is
controversial. Although β-lactam monotherapy is common, data to guide the choice between …

This study evaluated the pharmacodynamics of continuous infusion β-lactams against
pulmonary isolates of Gram-negative bacteria from patients managed in intensive care units …

Background Critically ill patients display altered pharmacokinetics and pharmacodynamics
and are more likely to be infected with more resistant pathogens. Beta-lactam antibiotics …